Sugi Predict

Sugi Predict / Compounds / SCHEMBL6862670

SCHEMBL6862670

SCHEMBL6862670

O=C1CCCc2nc(Br)sc21

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.63
▸ MAPK1 P28482 1/20 0.63
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ PIK3CD O00329 1/20 0.50
▸ PIK3CA P42336 1/20 0.50
▸ PIK3CB P42338 1/20 0.50
▸ PIK3CG P48736 1/20 0.50
▸ GRM5 P41594 1/20 0.47
▸ NPC1 O15118 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ TSHR P16473 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ FBP1 P09467 1/20 0.31
▸ PDK1 Q15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31136227 0.87 ALDH1A1 (0.47) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA
SCHEMBL167247 0.78 ALDH1A1 (0.61) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA
SCHEMBL2035154 0.78 ALDH1A1 (0.61) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA
SCHEMBL170013 0.78 ALDH1A1 (1.00) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA
Bromide SCHEMBL3450128 0.76 ALDH1A1 (0.96) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA
Hydrochloric Acid SCHEMBL30189955 0.76 ALDH1A1 (0.96) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA
SCHEMBL6118325 0.73 ALDH1A1 (0.56) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA
SCHEMBL31258748 0.73 ALDH1A1 (0.35) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA
SCHEMBL691842 0.73 ALDH1A1 (0.92) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA
SCHEMBL18237867 0.73 ALDH1A1 (0.56) ALDH1A1MAPK1SMN1; SMN2PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4626886-A1 JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS OnQuality Pharmaceuticals China Ltd. (CN) 2025-10-08 — — EP disclosed
WO-2025085527-A1 3βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF THE CLEVELAND CLINIC FOUNDATION (US) 2025-04-24 — — WO disclosed
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 — — US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 — — US disclosed
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 — — CN disclosed
CN-111689927-B Piperazinyl tetrahydrobenzothiazole oxime ether derivative and application thereof 南开大学 2022-07-12 — — CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 — — US disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 — — US disclosed
CN-111689927-A Piperazinyl tetrahydrobenzothiazole oxime ether derivative and application thereof 南开大学 2020-09-22 — — CN disclosed
EP-3484878-B1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-08-19 — — EP disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 — — WO disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 — — WO disclosed
EP-3107901-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS Piramal Enterprises Limited (IN) 2016-12-28 — — EP disclosed
US-9174953-B2 Bicyclic thiazoles as allosteric modulators of mGluR5 receptors JANSSEN PHARMACEUTICA NV (BE) 2015-11-03 — — US disclosed
US-9174953-B2 Bicyclic thiazoles as allosteric modulators of mGluR5 receptors JANSSEN PHARMACEUTICA NV (BE) 2015-11-03 — — US disclosed
WO-2015125085-A1 COMPOUNDS FOR USE AS GPR120 AGONISTS Piramal Enterprises Limited (IN) 2015-08-27 — — WO disclosed
EP-2513118-B1 BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2013-09-18 — — EP disclosed
US-20120252800-A1 BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-04 — — US disclosed
US-20120252800-A1 BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-04 — — US disclosed
WO-2011073347-A1 BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252800-A1 BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS GRM5, GRIK5, GRM2 ALDH1A1 4174/4885MAPK1 1976/4885SMN1; SMN2 2101/4885
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 ALDH1A1 1598/4885MAPK1 2622/4885SMN1; SMN2 3957/4885
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS LRRK2, PARK7, GDI2 ALDH1A1 1904/4885MAPK1 650/4885SMN1; SMN2 476/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 ALDH1A1 1598/4885MAPK1 2622/4885SMN1; SMN2 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.